Literature DB >> 27273328

Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents.

Michael Tsatsos1,2,3,4, Cheryl MacGregor2, Ioannis Athanasiadis3, Marilita M Moschos4, Parwez Hossain2, David Anderson2.   

Abstract

Ophthalmic herpes simplex viral keratitis is responsible for a range of ocular manifestations from superficial epithelial disease to stromal keratitis and endotheliitis. The Herpetic Eye Disease Study has guided the management of herpetic eye disease for almost twenty years, but newer medications such as valacyclovir are now available and are considered to have better bioavailability than acyclovir. In this review, we examine the existing evidence on the pathogenesis of different ophthalmic herpes simplex viral keratitis disease modalities and the role of oral and topically administered antiviral drugs in the treatment of herpes simplex viral keratitis.
© 2016 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  acyclovir; ganciclovir; herpes simplex keratitis; valacyclovir

Mesh:

Substances:

Year:  2016        PMID: 27273328     DOI: 10.1111/ceo.12785

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  40 in total

1.  A 54-year-old man with bilateral symmetrical circular corneal opacities.

Authors:  Colm McAlinden; Christopher P R Williams
Journal:  Digit J Ophthalmol       Date:  2020-06-21

Review 2.  Latent versus productive infection: the alpha herpesvirus switch.

Authors:  Orkide O Koyuncu; Margaret A MacGibeny; Lynn W Enquist
Journal:  Future Virol       Date:  2018-05-22       Impact factor: 1.831

3.  Successful Management of Herpes Simplex Keratitis With Oral Valganciclovir in Patients Unresponsive or Allergic to Conventional Antiviral Therapy.

Authors:  Neslihan Dilruba Koseoglu; Benjamin R Strauss; Pedram Hamrah
Journal:  Cornea       Date:  2019-06       Impact factor: 2.651

4.  Prior inhibition of AKT phosphorylation by BX795 can define a safer strategy to prevent herpes simplex virus-1 infection of the eye.

Authors:  Tejabhiram Yadavalli; Rahul Suryawanshi; Marwan Ali; Aqsa Iqbal; Raghuram Koganti; Joshua Ames; Vinay Kumar Aakalu; Deepak Shukla
Journal:  Ocul Surf       Date:  2019-11-23       Impact factor: 5.033

Review 5.  Update on the Management of Infectious Keratitis.

Authors:  Ariana Austin; Tom Lietman; Jennifer Rose-Nussbaumer
Journal:  Ophthalmology       Date:  2017-09-21       Impact factor: 12.079

6.  Red Eye: A Guide for Non-specialists.

Authors:  Andreas Frings; Gerd Geerling; Marc Schargus
Journal:  Dtsch Arztebl Int       Date:  2017-04-28       Impact factor: 5.594

Review 7.  Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation.

Authors:  Ann-Marie Lobo; Alex M Agelidis; Deepak Shukla
Journal:  Ocul Surf       Date:  2018-10-11       Impact factor: 5.033

Review 8.  Application of our understanding of pathogenesis of herpetic stromal keratitis for novel therapy.

Authors:  Naveen K Rajasagi; Barry T Rouse
Journal:  Microbes Infect       Date:  2018-01-09       Impact factor: 2.700

Review 9.  Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea.

Authors:  Lulia Koujah; Rahul K Suryawanshi; Deepak Shukla
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

10.  Bacterial Pigment Prodigiosin Demonstrates a Unique Antiherpesvirus Activity That Is Mediated through Inhibition of Prosurvival Signal Transducers.

Authors:  Rahul K Suryawanshi; Lulia Koujah; Chandrashekhar D Patil; Joshua M Ames; Alex Agelidis; Tejabhiram Yadavalli; Satish V Patil; Deepak Shukla
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.